



The Alzheimer's Disease Neuroimaging Initiative 3 Study

The Alzheimer's Disease Neuroimaging Initiative is a historic study of brain aging, providing researchers throughout the world access to ADNI data with the belief that open source is the best way to approach Alzheimer's.

ADNI 3 is the latest phase of the initiative. It is a non-treatment clinical research study to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in ongoing AD research.

Data from this research will help determine the best measures for diagnosis and disease monitoring, which will be used to accelerate the testing of therapeutic interventions and, ultimately, improve Alzheimer's disease prevention and care.

Who can participate?

Currently enrolling individuals who:

- are ages 55-90 with a diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's disease (AD) or are ages 65-90 with normal cognition
- have a reliable study partner who has frequent contact with the individual and is able to accompany the participant to study visits for the duration of the study
- are willing to participate in repeated imaging and biomarker collection

What does the study include?

If you agree and are eligible to participate in the study, you will be asked to come in for:

- an initial screening visit and a baseline visit
- an annual or biannual follow-up clinic visit

Screening procedures include:

- Brain imaging such as MRI and PET/CT scans
- Memory Testing
- Physical and Neurological Exam
- Lumbar Puncture
- Blood Draw

Before enrolling into the study, the participant and study partner must read, understand, and sign a formal consent form, which fully explains the study.

Compensation

Participants will be compensated for their time and travel.

For more information, contact
Jessica Nuñez at 215-662-4379 or
jessica.nunez@uphs.upenn.edu